«Radachlorin®» concentrate for production of intravenous solution 0,35%
1. «Radachlorin®» the most selective and quickly accumulates in the tumour tissue, thus:
a. reduces the duration of the medical intervention;
b. reduces the cost of drugs for anaesthesia;
c. reduces the costs of providing symptomatic postoperative treatment;
d. reduces the duration of inpatient treatments.
2. «Radachlorin®» has a long shelf life, which suggests the persistence of the active substance and, accordingly, the reliability of clinical effect of the drug.
3. «Radachlorin®» has the optimal (soft) dosing mode that reduces the toxic effects of on the body drug, reducing costs of health facilities for the maintenance of patients, but also increases the effectiveness of treatment in various pathological processes.
These studies were conducted at leading research institutes of the Russian Federation. In the study of the physicochemical properties of the drug substance «Radachlorin®», as well as its preclinical study was attended by leading Russian pharmaceutical research organization:
- Research Institute of Pharmacy and Pharmacopoeial Committee of the Ministry of health of Russia - Research Institute of biomedical chemistry of RAMS
- FSUE State Scientific Center for Antibiotics
- Institute of State Control of Medicines of the Pharmacological Committee of Ministry of Health of the Russian Federation
- Institute of Experimental Diagnostics and Therapy of Tumours, Blokhin Russian Oncological Scientific Center etc.
The materials of clinical study Reports «Radachlorin®» was obtained on the bases:
1. Blokhin Russian Oncology Scientific Center (2002-2004)
2. Hertsen Moscow Oncology Research Center (2002-2004)
3. Chelyabinsk Municipal Clinical Hospital №1 (2003-2004)
4. Vladimirskiy Moscow Regional Research Clinical Institute (2005-2007)
5. Pirogov Russian State Medical University (2005-2006)
6. Hertsen Moscow Oncology Research Center (2013-2015)
7. Pirogov Russian National Research Medical University (2013-2015)